# Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

> **NCT04541108** · EARLY_PHASE1 · RECRUITING · sponsor: **Presage Biosciences** · enrollment: 15 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **BIOLOGICAL:** Rilvegostomig
- **BIOLOGICAL:** Volrustomig
- **BIOLOGICAL:** Sabestomig
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04541108
- **Lead sponsor:** Presage Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-07-26
- **Primary completion:** 2031-12
- **Final completion:** 2031-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2024-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04541108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04541108, "Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04541108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*